Genmab A (GMAB) Shares Outstanding (2018 - 2026)
Genmab A's (GMAB) quarterly Shares Outstanding (Entity) came in at $64.7 million in Q4 2025, up 3.01% YoY from $62.8 million in Q4 2024, and up 3.01% on a QoQ basis from $62.8 million in Q4 2024.
Genmab A (GMAB) Shares Outstanding (2018 - 2026) Analysis & Trends
Genmab A (GMAB) has 7 years of Shares Outstanding (Entity) data on file, last reported at $64.7 million in Q4 2025.
- Quarterly Shares Outstanding (Entity) rose 3.01% year-over-year to $64.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $64.7 million (up 3.01% YoY) and the FY2025 annual result came in at $64.7 million, up 3.01% from the prior year.
- Shares Outstanding (Entity) improved to $64.7 million in Q4 2025, from $62.8 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $64.7 million in Q4 2025 to a low of $28.1 million in Q1 2021.
- A 4-year average of $46.0 million and a median of $45.6 million in 2023 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2024 — Shares Outstanding (Entity) soared 122.05% — and 2025, when it climbed 3.01%.
- Tracing GMAB's Shares Outstanding (Entity) over 4 years: stood at $28.1 million in 2021, then rose by 0.66% to $28.3 million in 2023, then soared by 122.05% to $62.8 million in 2024, then increased by 3.01% to $64.7 million in 2025.
- The last three Shares Outstanding (Entity) figures came in at $64.7 million (Q4 2025), $62.8 million (Q4 2024), and $28.3 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn | 64.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 64.72 Mn |
| Mar 31, 2026 | 64.72 Mn |
| Dec 31, 2025 | 64.72 Mn |
| Sep 30, 2025 | 66.14 Mn |
| Jun 30, 2025 | 66.14 Mn |
| Mar 31, 2025 | 66.14 Mn |
| Dec 31, 2024 | 66.14 Mn |
| Sep 30, 2024 | 66.02 Mn |
| Jun 30, 2024 | 66.02 Mn |
| Mar 31, 2024 | 66.02 Mn |
| Dec 31, 2023 | 66.02 Mn |
| Mar 31, 2021 | 65.32 Mn |
| Sep 30, 2020 | 63.13 Mn |
| Mar 31, 2020 | 63.13 Mn |
| Dec 31, 2019 | 63.13 Mn |
| Sep 30, 2019 | 61.38 Mn |
| Dec 31, 2018 | 61.38 Mn |